Share
ALL Hub
The ALL Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
Latest episode
Strategies to prevent relapse post HSCT / cellular therapy in B-ALL
51:50|During the ALL Hub Steering Committee meeting in November 2025, key opinion leaders met to discuss strategies to prevent relapse post hematopoietic stem cell transplantation (HSCT) / cellular therapy in B-cell acute lymphoblastic leukemia (B-ALL). The meeting opened with a presentation by Ibrahim Aldoss and featured a discussion including Charles Mullighan, José María Ribera, Sabina Chiaretti, Andre Baruchel, Wendy Stock, Daniel DeAngelo, and Anita Rijneveld. During his presentation, Aldoss highlighted that despite advances in multi-agent chemotherapy and novel immunotherapies allowing an increased number of patients to undergo allogeneic (allo) HSCT – a potentially curative approach in B-ALL – post-transplant relapse, as well as relapse following CAR T-cell therapy, remains a major cause of treatment failure. He discussed several studies exploring relapse-preventive measures post transplantation, including established strategies such as tyrosine kinase (TKI) maintenance in patients with Philadelphia-chromosome positive (Ph+) ALL, and newer strategies, such as the use of blinatumomab, inotuzumab ozogamicin, or prophylactic donor-derived CAR T-cell therapy, which have shown promising initial activity in patients with B-ALL. He also outlined the major considerations that influence the decision to initiate maintenance therapy after allo-HSCT or salvage therapy post-CAR T-cell therapy. This educational resource is independently supported by Pfizer. All content was developed independently by the steering committee in collaboration with SES. Funders were allowed no influence on the content of the discussion.
More episodes
View all episodes
How can therapeutic drug monitoring and premedication be applied in clinical practice to optimize pegaspargase treatment in patients with ALL?
04:46|The ALL Hub was pleased to speak with Carmelo Rizzari, University of Milano-Bicocca, Monza, IT. We asked, How can therapeutic drug monitoring and premedication be applied in clinical practice to optimize pegaspargase treatment in patients with acute lymphoblastic leukemia (ALL)? This educational resource is independently supported by Servier. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.What are the key clinical considerations for asparaginase-based regimens in pediatric vs AYA patients with ALL?
07:39|The ALL Hub was pleased to speak with Luke Maese, University of Utah Huntsman Cancer Institute and Primary Children's Hospital, Salt Lake City, US. We asked, What are the key clinical considerations for asparaginase-based regimens in pediatric vs adolescent/young adult (AYA) patients with acute lymphoblastic leukemia (ALL)? This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.Consolidation therapy in newly diagnosed adult patients with Ph-negative B-cell ALL
25:42|During the ALL Hub steering committee meeting, Mark Litzow chaired a discussion on consolidation therapy in newly diagnosed adult patients with Philadelphia chromosome-negative B-cell ALL.Optimizing treatment for adults with R/R Ph-negative B-cell ALL
32:33|During the ALL Hub Steering Committee meeting, Wendy Stock chaired a discussion on optimizing treatment for adults with relapsed/refractory Philadelphia chromosome-negative B-cell ALL.Key considerations when preparing patients with ALL for CAR T-cell therapy
26:09|During the ALL Hub Steering Committee meeting, André Baruchel chaired a discussion on “What are the key considerations when preparing patients with ALL for CAR T-cell therapy ?”, featuring Andrea Biondi, Anita Rijneveld, and José María Ribera. The discussion topics included: Key considerations when selecting patients: stable disease, degree of antigen expression, burden of bone marrow disease, and number of circulating tumor blasts Bridging therapy and lymphodepletion considerations The impact of prior exposure to blinatumomab and inotuzumab on CAR T-cell outcomes Indications for the use of tisagenlecleucel in pediatric ALL Indications for the use of brexucabtagene autoleucel in adult ALL
Global socioeconomic disparities in ALL: toxicity in Brazil and Guatemala
12:40|This series of podcasts covers global socioeconomic disparity in ALL. In this episode, the ALL Hub asked Eduardo Chapchap, Hospital Israelita Albert Einstein, São Paulo, BR and Federico Antillion, Unidad Nacional de Oncologia Pediatrica, Guatemala City, GT about disparities in toxicity and their management in ALL, including:· What are the toxicities you encountered while treating patients with ALL and how did you manage them? · What are the barriers contributing to poor toxicity management? Chapchap and Antillion discussed socioeconomic disparities in ALL across high middle-income countries (HMIC), low middle-income countries (LMIC), and within adult and pediatric populations. Chapchap mentioned common toxicities such as infections and neutropenia, which are becoming easier to manage considering the increased access to antifungal medications, antibiotics, and preventative measures. Early and long-term neurological toxicities are also common and, although these are more challenging to manage, there are preventative measures in place, such as reducing the dose of cytarabine and methotrexate, reducing the dose in older patients, omitting the use of cranial radiation, and supportive care measures. Other adverse effects, include asparaginase-related toxicities such as thrombosis in adult patients, are generally treated with prophylactic heparins and/or avoiding fibrinogen replacement. Hypertriglyceridemia and liver toxicities are common asparaginase toxicities that are often managed by dose reductions in patients who are overweight. Antillion discussed that febrile neutropenia and septic shock are often related to chemotherapy induction. Infection management involves the use of different types of prophylactic measures. Bleeding events also occur, which are related to a low platelet count. While patients can face asparaginase-related toxicities, the most common toxicities are severe cases of acute pancreatitis. Anthracycline-based medication can cause medium and long-term cardiac toxicities in pediatric ALL, which can impact quality of life.